222 related articles for article (PubMed ID: 30969158)
1. Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the
Moncur JT; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Kim AS
Arch Pathol Lab Med; 2019 Oct; 143(10):1203-1211. PubMed ID: 30969158
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on
Surrey LF; Oakley FD; Merker JD; Long TA; Vasalos P; Moncur JT; Kim AS
Arch Pathol Lab Med; 2019 Aug; 143(8):980-984. PubMed ID: 30865489
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.
Kim AS; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Moncur JT
JAMA Oncol; 2018 Jun; 4(6):838-841. PubMed ID: 29242895
[TBL] [Abstract][Full Text] [Related]
4. SPOT/Dx Pilot Reanalysis and College of American Pathologists Proficiency Testing for KRAS and NRAS Demonstrate Excellent Laboratory Performance.
Zehir A; Nardi V; Konnick EQ; Lockwood CM; Long TA; Sidiropoulos N; Souers RJ; Vasalos P; Lindeman NI; Moncur JT
Arch Pathol Lab Med; 2024 Feb; 148(2):139-148. PubMed ID: 37776255
[TBL] [Abstract][Full Text] [Related]
5. Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.
Devereaux KA; Souers RJ; Merker JD; Lindeman NI; Graham RP; Hameed MR; Vasalos P; Moncur JT; Lockwood CM; Xian RR
Arch Pathol Lab Med; 2023 Apr; 147(4):425-433. PubMed ID: 35687785
[TBL] [Abstract][Full Text] [Related]
6. Reporting Results of Molecular Tests: A Retrospective Examination of BRAF Mutation Reporting.
Treece AL; Gulley ML; Vasalos P; Paquette C; Lindeman NI; Jennings LJ; Bartley AN
Arch Pathol Lab Med; 2017 May; 141(5):658-665. PubMed ID: 28447902
[TBL] [Abstract][Full Text] [Related]
7. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
[TBL] [Abstract][Full Text] [Related]
8. A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices.
Nagarajan R; Bartley AN; Bridge JA; Jennings LJ; Kamel-Reid S; Kim A; Lazar AJ; Lindeman NI; Moncur J; Rai AJ; Routbort MJ; Vasalos P; Merker JD
Arch Pathol Lab Med; 2017 Dec; 141(12):1679-1685. PubMed ID: 29028368
[TBL] [Abstract][Full Text] [Related]
9. Rapid clinical mutational testing of
Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
11. Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.
Merker JD; Devereaux K; Iafrate AJ; Kamel-Reid S; Kim AS; Moncur JT; Montgomery SB; Nagarajan R; Portier BP; Routbort MJ; Smail C; Surrey LF; Vasalos P; Lazar AJ; Lindeman NI
Arch Pathol Lab Med; 2019 Apr; 143(4):463-471. PubMed ID: 30376374
[TBL] [Abstract][Full Text] [Related]
12. A Model Study of In Silico Proficiency Testing for Clinical Next-Generation Sequencing.
Duncavage EJ; Abel HJ; Merker JD; Bodner JB; Zhao Q; Voelkerding KV; Pfeifer JD
Arch Pathol Lab Med; 2016 Oct; 140(10):1085-91. PubMed ID: 27388684
[TBL] [Abstract][Full Text] [Related]
13. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data.
Nardi V; Tsuchiya KD; Kim AS; Bean LJH; Halley JG; Long TA; Szelinger S; Vasalos P; Thorson JA; Moyer AM; Moncur JT
Arch Pathol Lab Med; 2022 Apr; 146(4):451-461. PubMed ID: 34424952
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.
Lin MT; Mosier SL; Thiess M; Beierl KF; Debeljak M; Tseng LH; Chen G; Yegnasubramanian S; Ho H; Cope L; Wheelan SJ; Gocke CD; Eshleman JR
Am J Clin Pathol; 2014 Jun; 141(6):856-66. PubMed ID: 24838331
[TBL] [Abstract][Full Text] [Related]
16. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
[TBL] [Abstract][Full Text] [Related]
17. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
18. Four-Year Laboratory Performance of the First College of American Pathologists In Silico Next-Generation Sequencing Bioinformatics Proficiency Testing Surveys.
Furtado LV; Souers RJ; Vasalos P; Halley JG; Aisner DL; Nagarajan R; Voelkerding KV; Merker JD; Konnick EQ
Arch Pathol Lab Med; 2023 Feb; 147(2):137-142. PubMed ID: 35671151
[TBL] [Abstract][Full Text] [Related]
19. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
Pisapia P; Malapelle U; Roma G; Saddar S; Zheng Q; Pepe F; Bruzzese D; Vigliar E; Bellevicine C; Luthra R; Nikiforov YE; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Bihl M; Savic S; Bubendorf L; de Biase D; Tallini G; Hwang DH; Sholl LM; Vander Borght S; Weynand B; Stieber D; Vielh P; Rappa A; Barberis M; Fassan M; Rugge M; De Andrea CE; Lozano MD; Lupi C; Fontanini G; Schmitt F; Dumur CI; Bisig B; Bongiovanni M; Merkelbach-Bruse S; Büttner R; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2019 May; 127(5):285-296. PubMed ID: 31021538
[TBL] [Abstract][Full Text] [Related]
20. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
